Brain and nerve = Shinkei kenkyu no shinpo 2011-01-01

[Chronic subdural hematoma--recurrence and prevention].

Fumihiro Sakakibara, Nobusuke Tsuzuki, Yoichi Uozumi, Hiroshi Nawashiro, Katsuji Shima

Index: Brain Nerve 63(1) , 69-74, (2011)

Full Text: HTML

Abstract

Chronic subdural hematoma is one of the most common disorders observed in routine neurosurgical care. In the vast majority of cases, this disorder is treated by surgical evacuation, which usually yields a good prognosis. However, the recurrence rates after this initial procedure range from approximately 5% to 30%. In this study, we focused on the recurrence rate of chronic subdural hematoma and its prevention. We reviewed the risk factors for recurrence, surgical procedures used, perioperative management, timing of operation, and medical treatment.

Related Compounds

Related Articles:

The glial cell modulators, ibudilast and its amino analog, AV1013, attenuate methamphetamine locomotor activity and its sensitization in mice.

2012-03-15

[Eur. J. Pharmacol. 679(1-3) , 75-80, (2012)]

Phosphodiesterase inhibitors. Part 1: Synthesis and structure–activity relationships of pyrazolopyridine–pyridazinone PDE inhibitors developed from ibudilast

2011-01-01

[Bioorg. Med. Chem. Lett. 21(11) , 3307-12, (2011)]

Ibudilast, a pharmacologic phosphodiesterase inhibitor, prevents human immunodeficiency virus-1 Tat-mediated activation of microglial cells.

2011-01-01

[PLoS ONE 6(4) , e18633, (2011)]

Inhibition of paclitaxel-induced decreases in calcium signaling.

2012-11-02

[J. Biol. Chem. 287(45) , 37907-16, (2012)]

Ibudilast, a mixed PDE3/4 inhibitor, causes a selective and nitric oxide/cGMP-independent relaxation of the intracranial vertebrobasilar artery.

2011-01-15

[Eur. J. Pharmacol. 650(2-3) , 605-11, (2011)]

More Articles...